1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A

Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A

SSZSE:002020
11.34
CNY
+0.14
(+1.25%)
0.94EPS
13.48P/E
10.75BMarket Cap
Oct 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.61
1.91
2.06
2.45
2.76
3.39
4.26
4.09
4.24
4.39
4.65
4.85
4.94
4.97
Basic EPS, GAAP
0.11
0.17
0.24
0.26
0.33
0.43
0.61
0.82
0.75
0.77
0.72
0.83
0.92
0.93
Free Cash Flow per Basic Share
- -
0.18
0.04
0.21
0.34
0.31
0.23
0.23
-0.04
0.4
0.32
0.55
0.7
- -
Dividend per Share
0.05
0.05
0.07
0.07
0.08
0.16
0.24
0.3
0.28
0.3
0.3
0.3
0.35
- -
Book Value per Share
1.35
2.03
2.89
3.1
4.44
4.12
4.25
4.63
5.37
5.98
6.4
6.93
6.77
6.97
Tangible Book Value per Share
1.16
1.88
2.09
2.34
3.97
3.65
3.76
4.14
4.81
5.09
5.53
6.08
5.88
6.11
Basic Weighted Avg Shares
606
647
687
766
805
867
855
796
817
860
860
858
824
819
Sales/Revenue/Turnover
974
1,235
1,416
1,875
2,219
2,944
3,647
3,258
3,467
3,780
3,999
4,159
4,069
4,069
Operating Margin (%)
7.53
9.63
11.49
12.14
12.51
12.61
14.72
17.6
18.27
17.44
15.92
20.14
20.76
22.61
Depreciation Expense
42
51
59
80
87
91
106
123
150
167
220
295
287
- -
Net Income, GAAP
64
107
166
200
264
369
520
653
613
662
619
712
758
759
Effective Tax Rate (%)
15
15.63
15.29
15.96
23.85
10.6
13.5
13.92
11.66
10.99
11.95
14.79
11.3
11.62
Profit Margin (%)
6.6
8.67
11.73
10.65
11.91
12.54
14.27
20.04
17.67
17.52
15.48
17.12
18.63
18.64
Working Capital
105
536
816
765
2,127
1,683
1,715
1,568
1,872
1,466
1,279
770
1,394
2,325
LT Debt
12
- -
- -
- -
- -
- -
1
19
31
43
31
23
23
28
Total Equity
818
1,399
2,261
2,426
3,966
3,600
3,711
3,933
4,899
5,172
5,540
6,002
5,870
6,038
Return on Invested Capital (%)
5.49
8.74
8.31
7.48
2.7
9.44
13.09
15.58
13
12.6
10.99
11.69
12.15
12.51
Return on Capital (%)
7.75
9.34
9.15
8.23
7.94
9.65
13.5
15.79
13.05
12.54
10.96
11.68
12.04
12.31
Return on Common Equity (%)
8.09
9.66
9.19
8.69
8.39
9.84
14.29
17.16
13.95
13.23
11.61
12.4
12.84
12.98

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
291
133
182
LT Borrowings
- -
- -
- -
LT Finance Leases
23
27
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
861
861
861
Market Capitalization
16,342
13,535
10,754

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,301
3,193
3,894
Cash, Cash Equivalents & STI
850
1,100
1,117
Accounts Receivable, Net
785
731
728
Inventories
766
814
800
Total Current Liabilities
1,907
1,572
1,569
Payables & Accruals
- -
- -
- -
ST Debt
291
133
182
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.4%
8.68%
-2.19%
Free Cash Flow
-70.79%
-232.42%
21.66%
Net Income, GAAP
17.56%
3.37%
6.46%
Sales/Revenue/Turnover
11.98%
4.62%
-2.14%
Total Cash Common Dividend
- -
- -
10.28%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,061
1,089
1,059
950
4,159
2025
956
1,060
- -
1,021
4,069
2026
923
1,064
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.27
0.2
0.16
0.83
2025
0.2
0.28
- -
0.22
0.92
2026
0.2
0.23
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
- -
0.35
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gang Lü
Full Time Employees
3,732
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 800, East Road Shaoxing China 312500
IPO Date
Jun 29, 2004
Website
jingxinpharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) researches, develops, produces and sells pharmaceutical products and medical devices primarily in China with expanding international operations. Founded in 1990 and headquartered in Xinchang, Zhejiang Province, China, the company operates in four main segments encompassing chemical preparations including anti-infectives such as azithromycin tablets, cefpodoxime proxetil tablets and cefodizime sodium for injection; cardiovascular medicines such as rosuvastatin calcium tablets and amlodipine; central nervous system drugs such as sertraline hydrochloride tablets, levetiracetam tablets and pramipexole hydrochloride; traditional Chinese medicines; biological agents; active pharmaceutical ingredients (APIs) including ciprofloxacin hydrochloride, levofloxacin hydrochloride, enrofloxacin, simvastatin, clopidogrel hydrogen sulfate, apixaban, rivaroxaban and memantine hydrochloride; and medical devices from subsidiary Shenzhen Juyi Display Technology Co., Ltd. such as diagnostic, surgical and clinical medical displays, medical large screens, integrated machines and ultrasonic displays. The company maintains a global research layout with 10 joint ventures and R&D laboratories worldwide, targeting cardiovascular, cerebrovascular, neurological, psychological and digestive tract therapeutic areas for hospital, retail and export markets across Asia, Europe and North America. Recent developments include an equity buyback plan announced in January 2025, under which the company repurchased 47.3 million shares or 5.55% of its capital for CNY 608.72 million by September 2025; participation in international events such as CPHI Frankfurt in October 2025 and CPHI China in June 2025 to expand overseas partnerships; and ongoing advancements in R&D for innovative formulations amid strategic focus on strengthening pharmaceuticals while growing medical devices.